Xencor, Inc. (XNCR)
NASDAQ: XNCR · Real-Time Price · USD
12.00
+0.39 (3.36%)
Mar 13, 2026, 4:00 PM EDT - Market closed
Xencor Revenue
In the year 2025, Xencor had annual revenue of $125.58M with 13.65% growth. Xencor had revenue of $28.24M in the quarter ending December 31, 2025, a decrease of -59.67%.
Revenue (ttm)
$125.58M
Revenue Growth
-1.68%
P/S Ratio
6.91
Revenue / Employee
$482,985
Employees
260
Market Cap
880.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 125.58M | 15.08M | 13.65% |
| Dec 31, 2024 | 110.49M | -64.12M | -36.72% |
| Dec 31, 2023 | 174.62M | 10.04M | 6.10% |
| Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
| Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
| Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
| Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
| Dec 31, 2018 | 40.60M | -5.55M | -12.02% |
| Dec 31, 2017 | 46.15M | -62.87M | -57.67% |
| Dec 31, 2016 | 109.02M | 81.26M | 292.70% |
| Dec 31, 2015 | 27.76M | 18.24M | 191.62% |
| Dec 31, 2014 | 9.52M | -652.00K | -6.41% |
| Dec 31, 2013 | 10.17M | 648.00K | 6.80% |
| Dec 31, 2012 | 9.52M | 2.68M | 39.06% |
| Dec 31, 2011 | 6.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.72B |
| MannKind | 348.97M |
| Valneva SE | 211.09M |
| UroGen Pharma | 109.79M |
| Inventiva | 19.93M |
| KalVista Pharmaceuticals | 1.43M |
| Adlai Nortye | -1.35M |
XNCR News
- 2 days ago - Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 9 days ago - Xencor Announces Change to Ultomiris® Royalty Revenue Forecast - Business Wire
- 16 days ago - Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 18 days ago - Xencor to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - Business Wire
- 2 months ago - Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 - Seeking Alpha
- 3 months ago - Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - Business Wire
- 4 months ago - Xencor Reports Third Quarter 2025 Financial Results - Business Wire